Abstract. Neurotrophins enhance the survival of cells in the nervous system under both physiological and pathological conditions, such as those caused by disease or trauma. We recently demonstrated that expression of brain-derived neurotrophic factor (BDNF) was up-regulated in neurons and glia after compression-induced spinal cord injury (SCI). We show here the effects of BDNF on the oligodendrocyte survival and functional recovery after SCI. The effects of intrathecally administered BDNF on both Cu/Zn superoxide dismutase (CuZnSOD) and myelin basic protein (MBP) expression were examined using rats that had received compression-induced spinal cord injury. CuZnSOD expression in the spinal cord was down-regulated within 24 h of compression-induced injury and then recovered. Continuous infusion of BDNF inhibited the acute downregulation of CuZnSOD expression. In situ hybridization showed that CuZnSOD was expressed in both neurons and glia. Although MBP expression was greatly reduced after injury, BDNF administration promoted the recovery of MBP expression nearly to a control level after 2 wk. Furthermore, BDNF administration also prompted behavioral recovery. These results suggest BDNF's usefulness in human clinical applications. The attenuation of CuZnSOD down-regulation may be related to a protective effect of BDNF and the promotion of MBP up-regulation may be related to a long-lasting restorative effect.
INTRODUCTION
The nervous system of adult mammals loses the ability to regenerate new neurons in place of lost ones. In the central nervous system (CNS), the regeneration of nerves is inhibited under normal conditions; while in the peripheral nervous system, there appears to be some capacity for regeneration. This suggests the existence of strong self-defense mechanisms in the CNS, which act to promote the survival of existing neurons and axons. Neurotrophic factors are thought to play key roles in the processes underlying these defense mechanisms. Neurotrophins possess at least 2 distinct functions: promotion of axonal regeneration in injured neurons, and protection of neurons or glia from insult. These effects may be found not only during the course of neurodegenerative diseases such as Parkinson disease (1) and amyotrophic lateral sclerosis (2) (3) (4) (5) , but are also apparent following stroke (6, 7) and other neuronal insults (8) (9) (10) (11) .
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which is due to a disruption of the flow of information passing through the long spinal tracts (12) (13) (14) (15) . Previous reports suggest that neurotrophins such as brain-derived neurotrophic factor (BDNF), neurotrophin 3 (NT3) and ciliary neurotrophic factor are effective in the treatment of damage to the spinal cord. For example, injections of NT3 promote sprouting of corticospinal axons following SCI (16) . Administration of neurotrophins promotes corticospinal axonal growth into transplanted fetal tissue (17) . Simultaneous administration of BDNF and NT3 following a graft of Schwann cells into transected spinal cord enhances regeneration of connections within the brainstem-spinal pathway (18) . A graft of NT3-producing fibroblasts in the spinal cord following hemisection of dorsal spinal cord facilitates regeneration of the corticospinal tract and partially ameliorates functional deficits (19) . However, most of the existing studies concerning the effects of neurotrophins in the spinal cord have focused on axonal regeneration, while the neuroprotective effects of neurotrophins had not been sufficiently elucidated. We recently reported that BDNF expression is acutely up-regulated after SCI in the different cell types including neurons and glia (20) . These data suggest that BDNF has protective effects on neurons and glia from a number of harmful factors in the acute phase.
Superoxide dismutase (SOD) is one of the major free radical scavengers that limits neural tissue damage wrought by free radicals through multiple mechanisms, including excitotoxicity, and disturbance of metabolism and intracellular calcium homeostasis. It has attracted attention because a mutation in its gene causes familial amyotrophic lateral sclerosis (21 SOD after SCI reduces neural tissue damage and facilitates functional recovery (22) . Since SOD is important in protecting neural tissue after SCI, it may reflect the protective capacity of neural tissue from SCI.
Myelin basic protein (MBP) is a major component of central myelin. Wrathall examined the change in MBP mRNA expression during the course of spinal cord tract restoration after SCI and reported that myelination may be affected by changes in the transcriptional regulation of myelin protein genes and by altered distribution of myelin producing cells (23) . Bartholdi examined changes in MBP mRNA levels after spinal cord transection and reported that the reactive response of surviving oligodendrocytes may be an important component of local repair mechanisms (24) . Thus, up-regulation of MBP expression may reflect the axonal repair response that leads to recovery of the spinal cord function.
Here we demonstrate the effects of BDNF after SCI on Cu/Zn superoxide dismutase (CuZnSOD), one subtype of the SODs, and MBP expression, which are thought to reflect the defensive reaction of the neural tissue against SCI. In addition, we show histological and behavioral experiments to directly evaluate the effects of BDNF.
MATERIALS AND METHODS

Animal Model of SCI
Laminectomies were performed on 8-wk-old male Wistar rats (180-200 g) (SLC, Hamamatsu, Japan) at the T8 level under Halothane anesthesia. We produced incomplete injury to the rat spinal cord as described previously (20) . The dural tube was compressed with a steady load of 50 g for 5 min at the site of the T8 laminectomy. T8 laminectomies were also performed on sham-operated rats that did not receive the compression-induced injury. All animals were treated and cared for in accordance with the Chiba University School of Medicine guidelines pertaining to the treatment of experimental animals.
Administration of BDNF
A silicone tube, 0.5 mm in diameter, was inserted intrathecally approximately 1 cm in a rostral direction in the interlaminar space at the L3/4 level just after the SCI. The tip of the tube was positioned between L1 and L2. The cannula was connected to an osmotic minipump (Model 2002, Alzet, Palo Alto, CA) containing 1 g/ml recombinant human BDNF in phosphate-buffered saline (PBS) in the BDNF group. PBS was substituted for the BDNF solution in the vehicle control group. BDNF was supplied by Sumitomo Pharmaceuticals (Osaka, Japan). Pumps were placed subcutaneously and continuously delivered the solutions at the rate of 0.5 l/h (BDNF 12 g/day). The infusion was started just after SCI and continued for 2 wk.
Preparation of cDNA
Rat CuZnSOD cDNA (nt 19-606, accession number Y00404) and rat MBP cDNA (nt 56-397, accession number M25889) were prepared by PCR amplification and subcloned into a pBluescript II vector (Stratagene, La Jolla, CA).
Northern Blot Analysis
Rats were analyzed at 6 h, 24 h, 3 days, 1 wk, 2 wk, and 4 wk after injury (n ϭ 5 at each time point in the BDNF-treated and vehicle-treated groups and n ϭ 5 in the sham-operated group). Animals were deeply anesthetized with intraperitoneal injection of pentobarbital (50 mg/kg) and decapitated. Segments of spinal cord around the injured site, approximately 12 mm long, were quickly removed, frozen in liquid nitrogen and stored at Ϫ70ЊC. These corresponded in length to 3 vertebrae, including the traumatized parts as well as adjacent rostral and caudal perifocal regions. Total RNA was isolated with TRIZOL (Life Technologies, Grand Island, NY). RNA samples (10 g) were separated by agarose-formaldehyde gel electrophoresis and transferred to nylon membranes (Hybond-N, AmershamPharmacia, Piscataway, NJ). Membranes were hybridized with a 32 P-labeled probe prepared by random-primed labeling using rat CuZnSOD or MBP cDNA as a template, then washed and exposed to X-ray films. Integrated density of each band measured using NIH image was statistically analyzed.
In Situ Hybridization
Sense and antisense RNA probes were transcribed in vitro from linearlized plasmids containing CuZnSOD or MBP cDNA using a digoxigenin (DIG)-RNA labeling mixture (Roche Diagnostics, Branchburg, NJ) and T3 or T7 RNA polymerase (Takara, Tokyo, Japan) in accordance with the manufacturer's protocols. Rats at 3 days after SCI (n ϭ 15: 5 BDNF-treated, 5 vehicle-treated, and 5 sham-operated) were used for CuZn-SOD staining and rats at 7 days after SCI (n ϭ 15: 5 BDNFtreated, 5 vehicle-treated, and 5 sham-operated) were used for MBP staining. These rats were deeply anesthetized and transcardially perfused with ice-cold 4% paraformaldehyde in 0.1 M sodium phosphate buffer, pH 7.4. Spinal cord tissues were dissected and further fixed overnight in the same solution at 4ЊC. After embedding in paraffin, serial cross sections of the tissue (6 m thick) were cut and placed on aminopropylsilane (APS)-coated glass slides (Matsunami, Tokyo, Japan). Sections were then deparaffinized, stained by in situ hybridization as described previously (20) . Five coronal sections of spinal cord were selected for staining from regions 1 to 2 mm rostral and caudal to the center of compression. These regions included both the compressed portion of the cord and adjacent uncompressed portions. Because we detected no differences between rostral and caudal sections in the degree of injury, we did not distinguish between them. CuZnSOD and MBP mRNA-positive cells were counted and statistically analyzed.
Immunohistochemical Cell Classification
Serial sections adjacent to those used for in situ hybridization were immunostained. After deparaffinization, sections were washed with PBS for 10 min and blocked with 3% skim milk in PBS overnight at 4ЊC. Sections were then incubated overnight at 4ЊC with anti-glial fibrillary acid protein (GFAP) antibody (G3893, Sigma, St. Louis, MO) diluted 1:400 in PBS or with anti-adenomatous polyposis coli (APC) antibody (CC-1, Calbiochem-Novabiochem, Cambridge, MA) (25) CuZnSOD expression markedly decreased 24 h after injury and returned to normal levels at 1 wk in the vehicle control group. Although CuZnSOD expression also decreased within 24 h in the BDNF-treated group, the degree of decrease was less obvious. CuZnSOD expression increased over the control level by 3 days. A high level of MBP expression was observed in the spinal cord of sham-operated rats. MBP expression decreased remarkably 24 h after injury and was maintained at low levels thereafter in the vehicle control group. However, in the BDNF-treated group, decrease of MBP expression was milder and expression gradually recovered 3 days after injury. Its recovery continued up to 4 wk even though the administration of BDNF was terminated at 2 wk. The lower panel shows 18 s and 28 s rRNA bands stained with ethidium bromide after agarose gel electrophoresis. B: Quantitative analysis of CuZnSOD expression after SCI. Integrated density of bands in the Northern blot analysis measured using NIH image was statistically analyzed. Expression of CuZnSOD mRNA was significantly reduced 24 h after injury (p Ͻ 0.01) and returned nearly to the normal level 3 days after injury (p Ͻ 0.05) in the vehicle group. In contrast, no significant reduction of the expression was observed in the BDNF-treated group during 4 wk. Expression levels of CuZnSOD were significantly higher in the BDNF-treated group at 6 h (p Ͻ 0.01) and 24 h (p Ͻ 0.05) after injury. Error bars show the mean Ϯ 1 standard error. ** p Ͻ 0.01, * p Ͻ 0.05, analysis using the Mann-Whitney U-test and Scheffe's test for multiple comparisons (n ϭ 65). C: Quantitative analysis of MBP expression after SCI. Integrated density of bands in the Northern blot analysis measured using NIH image was statistically analyzed. Expression of MBP was significantly reduced 3 days after injury (p Ͻ 0.01) and remained at low levels up to 4 wk in the vehicle group. In contrast, the downregulation was milder in the BDNF-treated group and the obvious recovery of the expression was observed at 2 wk and 4 wk. Expression levels of MBP were significantly higher in the BDNF treated group at 2 wk (p Ͻ 0.01) and 4 wk (p Ͻ 0.01) after injury. Error bars show the mean Ϯ 1 standard error. ** p Ͻ 0.01, analysis by Mann-Whitney U-test and Scheffe's test for multiple comparisons (n ϭ 65).
with the Vectastain ABC Kit (Vector Laboratories) for 2 to 4 h at room temperature. Sections were stained with 0.05% diaminobenzidine tetrahydrochloride, 0.1% ammonium nickel (II) sulfate hexahydrate, and 0.03% H 2 O 2 in Tris-buffered saline, pH 7.5.
Adjacent sections were also stained using tomato lectin (26) . After blocking, sections were incubated overnight at 4ЊC with 20 g/ml biotin-labeled tomato lectin (L0651, Sigma) in TBS. After washing with PBS, sections were colored with the same procedure used for immunostaining.
Immunohistochemical Analysis of Oligodendrocyte Survival
Rats at 3 days after SCI (n ϭ 15: 5 BDNF-treated, 5 vehicletreated, and 5 sham-operated) and rats at 7 days after SCI (n ϭ 10: 5 BDNF-treated and 5 vehicle-treated) were used for APC immunostaining (25) . Five coronal sections (6 m thick) selected from the same regions used for in situ hybridization were stained. The numbers of APC-positive cells were counted and statistically analyzed.
Behavioral Study
Neurological function of rat hindlimbs was assessed by blinded observers using an established multiple test method including motor score, incline plane, swim test, toe spread, placing, withdrawal reflex and righting (27) (n ϭ 10: 5 BDNFtreated, 5 vehicle-treated). We used the behavioral scoring system reported by Baffour et al (28) . Grades were compiled to create combined behavioral scores and total scores involved summation of all test scores. The total score ranged from 100 for a normal unoperated rat to zero for a completely paralyzed animal. The motor score, toe spread, placing, and withdrawal reflexes to extension, pain, and pressure, as well as righting, were assessed for each hindlimb independently. If 2 scores differed, the higher one was used for calculating the combined behavioral scores (27) .
Statistical Analysis
Data were expressed as the mean Ϯ1 standard error (SE). The integrated density of bands in the Northern blot analyses (CuZnSOD and MBP) was evaluated by Mann-Whitney U and Kruskal-Wallis tests. The number of CuZnSOD, MBP, and APC-positive cells was evaluated by Mann-Whitney U-test. Behavioral scores were evaluated by a repeated measure ANOVA. In cases where the Kruskal-Wallis test and ANOVA were significant (p Ͻ 0.05), post hoc pairwise comparisons were performed using Scheffe's test to compare significant differences among groups.
RESULTS
Northern Blot Analysis after SCI
We observed temporal changes in CuZnSOD expression in the rat spinal cord with compression-induced injury (Fig. 1A, B) . Expression of CuZnSOD mRNA was immediately and greatly reduced in the spinal cord after injury in the rats receiving vehicle only. Expression reached a minimum level, which is about one third of a control (sham-operated) level 24 h after injury (p Ͻ 0.01), and gradually returned to the control level from 3 days to 1 wk after the injury. Thereafter CuZnSOD mRNA again tended to decrease below the control level. In contrast, levels of CuZnSOD mRNA in the spinal cord after injury in the rats receiving BDNF showed no significant reduction and were maintained almost at the control level during 4 wk. Although expression also reached a minimum level 24 h after injury, its levels were significantly higher than those observed in the vehicle group at 6 h (p Ͻ 0.01) and 24 h (p Ͻ 0.05).
The maintenance of axons and axonal myelination was assessed by observing temporal changes of MBP expression (Fig. 1A, C) rats, a high level of MBP expression was detected. However, the expression dramatically decreased in the vehicle group to about one third of a control level up to 3 days after injury (p Ͻ 0.01) and thereafter remained at low levels up to 4 wk after injury. In contrast, no significant diminishment of MBP expression was observed in the spinal cord of the BDNF-treated group. The expression gradually tended to increase from 1 to 4 wk after injury and was maintained significantly higher levels than that in the vehicle group at 2 wk and 4 wk (p Ͻ 0.01). It is notable that BDNF administration was terminated 2 wk after injury.
In Situ Hybridization of CuZnSOD and MBP
After the compression-induced injury, the central region of the spinal cord was severely damaged, although the peripheral rim of the white matter was relatively spared in this model (Figs. 2C-F, 5C-F). The damage of the white matter was less severe in the BDNF-treated group than in the vehicle group. We studied spatial changes of CuZnSOD and MBP expression after SCI by in situ hybridization. A CuZnSOD mRNA hybridization signal was observed both in neurons and glia in the spinal cord of sham-operated rats ( Fig. 2A, B) . Glial staining was distributed widely in the white matter. Although the numbers of CuZnSOD-positive cells were greatly reduced in the central region both in the BDNF-treated and vehicle groups, the number of CuZnSOD-positive cells in the BDNF-treated group was significantly larger than that in the vehicle group 3 days after SCI (p Ͻ 0.01) (Figs. 2C-F, 3) . Most of the CuZnSOD-expressing cells in the white matter were identified as oligodendrocytes, since they were costained with the anti-APC antibody, a marker of oligodendrocytes (25) (Fig. 4A, B) . Distribution patterns of tomato lectin staining, a marker of microglia (26) and GFAP immunostaining, a marker of astrocytes, were different from that of CuZnSOD-positive cells (data not shown).
Many MBP-expressing cells were observed in the white matter of the spinal cord of sham-operated rats (Fig. 5A, B) . One week after the SCI, some MBP-positive cells were still found along the peripheral region of the white matter spared from injury in the BDNF-treated group (Fig. 5E, F) , whereas the number of MBP-positive cells was significantly reduced in the vehicle group at this period (p Ͻ 0.01) (Figs. 5C, D, 6 ).
Immunohistochemical Analysis of Oligodendrocyte Survival
Oligodendrocyte survival after SCI was evaluated by APC immunolabeling (25) . The number of APC-positive cells was greatly reduced 6 to 24 h after SCI and then gradually increased 3 days to 1 wk later (Fig. 8) . Three days after SCI, APC-positive cells were distributed along the peripheral regions of the white matter in the both groups (Fig. 7A-D) . However, the number of APC-positive cells of the BDNF-treated group was significantly larger than that of the vehicle group at both 3 days (p Ͻ 0.01) and 1 wk (p Ͻ 0.05) after SCI (Fig. 8) .
Behavioral Analyses
We performed behavioral analyses of the BDNF-treated and vehicle control groups to assess the effect of BDNF on protection or recovery of behavioral functions after SCI. Motor functions tested by a motor score, inclined plane, and a swim test showed statistically significant higher scores in the BDNF-treated group than in the vehicle group (Fig. 9A-C) . The recovery of motor function in the BDNF-treated group was especially evident in the motor score and swim test. Although scores of the BDNF-treated group tended to be higher in some testsincluding toe spread, placing, withdrawal reflex, and righting-which reflect deep and superficial sensibility, statistical significance was not observed. The BDNFtreated group showed significantly (p Ͻ 0.01) higher values in the total score obtained from the summation of all test scores.
DISCUSSION
BDNF diminishes up-regulation of neuronal nitric oxide synthase (nNOS) expression in the injured spinal cord and reduces signs of blood-spinal cord barrier damage, edema, and cell injury (29, 30) . BDNF also reduces lesion size and suppresses neuronal cell death after SCI (31) . However, with the exception of a report by Gong et al, in which BDNF treatment of dopaminergic neurons increases CuZnSOD activity and suppresses dopamineinduced cell death in vitro (32) , there have been no reports directly demonstrating the effect of BDNF on CuZnSOD expression.
CuZnSOD shows a characteristic change of expression after SCI. The acute down-regulation may be due to a loss of CuZnSOD expressing cells or a reduction in cell activity. The subsequent up-regulation may be the response of cells to injury. We demonstrated here that BDNF administration attenuated the acute down-regulation of CuZnSOD expression in the injured spinal cord in vivo. The histological studies showed that BDNF suppressed the glial cell death in the white matter after SCI. There were more CuZnSOD expressing glia in the white matter of the BDNF-treated group. These data suggest that BDNF has an effect on oligodendrocytes in the acute phase of SCI by inducing proteins that possess neuroprotective functions, such as CuZnSOD. Effects of BDNF on neurons in the central region at the injured site were not obvious; possibly because of relatively poor penetration of the infused BDNF into the central gray matter, as suggested by Jakeman et al (33) . In preliminary experiments, we observed full-length expression of TrkB, a high affinity receptor of BDNF, in spinal cord oligodendrocytes (data not shown). These data suggest that BDNF acts directly on oligodendrocytes.
BDNF did not attenuate the acute down-regulation of MBP expression, but it did promote the late up-regulation after SCI; late up-regulation continued after the termination of BDNF administration. The protective effect of BDNF on differentiated oligodendrocytes cannot account for the continued up-regulation of MBP expression, as fully differentiated oligodendrocytes neither proliferate nor contribute to remyelination after injury (34) . However, BDNF promotes myelinogenesis and axonal regeneration by inducing the differentiation of oligodendrocyte progenitor cells (35) . These lines of evidence suggest that late up-regulation of MBP expression is mainly due to BDNF's capacity to induce differentiation of oligodendrocyte progenitor cells. The significant increase of oligodendrocytes produced by BDNF administration at 3 days after SCI, when no significant difference in MBP levels was observed between the BDNF-treated and control groups, may be due to the protection of differentiated oligodendrocytes.
Some studies have previously reported effects of BDNF on behavioral recovery in vivo (33, 36) , and have emphasized the importance of BDNF's acute effects on neurons, such as direct stimulation (33) . In this study, BDNF was also found to facilitate behavioral recovery after SCI. In fact, behavioral measures showed significant improvements by 1 wk after BDNF treatment, although no significant difference was observed in MBP expression levels between the BDNF-treated and control groups until 2 wk after injury. Thus, we do not rule out the possibility that direct stimulation of neurons by BDNF contributes to functional recovery. However, based on the data presented here, we propose that the long-lasting effects of BDNF on neural structures after the acute phase of injury are more important for behavioral recovery.
Intrinsic BDNF expression was up-regulated in glia at the injury site following SCI (24, 37) . Our previous quantitative study using the same contused model further demonstrated that BDNF mRNA expression is acutely upregulated and reaches a maximum level 24 h after injury (24) . Although the contribution of intrinsic BDNF expression complicates interpretation of the data in the present study, the effects of extrinsic BDNF on oligodendrocytes were clearly demonstrated. Evidence suggests that intrinsic and extrinsic BDNF exert the same effects and that extrinsic BDNF administration strengthens the effects of intrinsic BDNF.
Finally, further investigation of variables such as optimal dosage, application period, and route are required, and it is necessary to distinguish between the temporal and long-lasting effects of the BDNF treatment. Relationships to other neurotrophins, such as NT-3 and insulin-like growth factor-I (IGF-I), and free-radical mechanisms, including nNOS, should also be explored. Nonetheless, we believe that our present study provides sound basic data suggesting BDNF's usefulness in human clinical applications; in particular as an effective treatment of SCI and an aid to the surgical treatment of myelopathy.
